Search 

There are multiple suppliers and distributors of the organ preservation solutions developed by Drs. Belzer and Southard at the University of Wisconsin. All patents on the formulations used in Belzer UW® Solutions (cold storage and machine perfusion) expired in 2006. Bridge to Life has an exclusive trademark license from the Wisconsin Alumni Research Foundation (WARF) for the trademark Belzer UW®.

In fact, WARF holds an equity position in Bridge to Life Ltd., a WARF startup company. We proudly honor the name of Dr. Belzer and the institution that developed the UW organ preservation solution, which is still the “gold standard” in organ preservation.

In 2008 the Leducq Family Trust established Broadview Ventures, Inc.(Broadview). Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures.

By making funding available at a critical moment in the development of new technology, the Leducq Family Trust is taking a leadership position in venture philanthropy by finding creative ways to support translational research in order to bring the advancements of science to the care of patients.

Nishant "Nish" Rastogi shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.

CTEXDEV develops Augmentative and Alternative Communication (AAC) applications called CommunicoTool, to help non-verbal individuals to communicate.

Our innovative solution

 CommunicoTool is an Augmentative and Alternative Communication (AAC) application that provide language communication features including: pictures and pictograms, prerecorded voice, speech synthesis, speech/pain assessment, time management. The application is fully configurable by the end users. Our service is available in French and English in a bilingual version.

CommunicoTool is an application for tablets suitable for patients with ASD, Stroke, LAS, Cerebral pulsy, with language and communication disorders. Just for ASD, The CDC (Centers for Disease Control and Prevention) estimates about 1 percent of the world population (7 billion) has autism spectrum disorder, and more than 25% of them are non-verbal. 

ASD / Stroke / LAS / Cerebral pulsy

Accessibility / price / Innovation / Configurable

CHEQUE SANTE

The costs of healthcare become more and more disabling for the modern-day families. Because of these costs, they tend to avoid taking medical appointments. Our objective is to allow every individual to be the master of his own health capital.

Firms, Works Council, Mutual insurance companies, Insurances?

Prepaid voucher, Online appointment setting, Intelligent health record, Directory of the healthcare professionals

Welcome to the Center for Human Reproduction (CHR), a leading fertility center located in New York City. CHR is known as a “fertility center of last resort,” primarily serving patients who have previously failed treatments elsewhere. Among CHR’s areas of special expertise are treatments of “older” ovaries, whether due to advanced female age or premature ovarian aging (POA), immunological problems affecting reproduction, repeated pregnancy loss, endometriosis, polycystic ovary syndrome (PCOS), tubal disease, male factor infertility, etc.

Harnessing the brain’s immune system to fight neurodegeneration.

CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.

CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI). The Company aims to initiate Phase 3 trials in 2015. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain.

Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.

The Private Company Access team leverages Citigroup’s strength and expertise in Institutional Sales and Trading to assist emerging growth companies with their investor relations objectives.
• Institutional investors are increasingly looking for access to emerging growth companies for direct investments, as well as to better understand looming risks to the public companies they own
• Growth-oriented companies are staying private longer, but need access to capital from institutional-type sources